Computational design of novel protein–protein interactions – An overview on methodological approaches and applications

Protein–protein interactions (PPIs) govern numerous cellular functions in terms of signaling, transport, defense and many others. Designing novel PPIs poses a fundamental challenge to our understanding of molecular interactions. The capability to robustly engineer PPIs has immense potential for the development of novel synthetic biology tools and protein-based therapeutics. Over the last decades, many efforts in this area have relied purely on experimental approaches, but more recently, computational protein design has made important contributions. Template-based approaches utilize known PPIs and transplant the critical residues onto heterologous scaffolds. De novo design instead uses computational methods to generate novel binding motifs, allowing for a broader scope of the sites engaged in protein targets. Here, we review successful design cases, giving an overview of the methodological approaches used for templated and de novo PPI design.     

An accurate binding interaction model in de novo computational protein design of interactions: If you build it,they will bind

Computational protein design efforts aim to create novel proteins and functions in an automated manner and, in the process, these efforts shed light on the factors shaping natural proteins. The focus of these efforts has progressed from the interior of proteins to their surface and the design of functions, such as binding or catalysis. Here we examine progress in the development of robust methods for the computational design of non-natural interactions between proteins and molecular targets such as other proteins or small molecules. This problem is referred to as the de novo computational design of interactions. Recent successful efforts in de novo enzyme design and the de novo design of protein–protein interactions open a path towards solving this problem. We examine the common themes in these efforts, and review recent studies aimed at understanding the nature of successes and failures in the de novo computational design of interactions. While several approaches culminated in success, the use of a well-defined structural model for a specific binding interaction in particular has emerged as a key strategy for a successful design, and is therefore reviewed with special consideration.     

Extension of a de novo TIM barrel with a rationally designed secondary structure element

The ability to construct novel enzymes is a major aim in de novo protein design. A popular enzyme fold for design attempts is the TIM barrel. This fold is a common topology for enzymes and can harbor many diverse reactions. The recent de novo design of a four‐fold symmetric TIM barrel provides a well understood minimal scaffold for potential enzyme designs. Here we explore opportunities to extend and diversify this scaffold by adding a short de novo helix on top of the barrel. Due to the size of the protein, we developed a design pipeline based on computational ab initio folding that solves a less complex sub‐problem focused around the helix and its vicinity and adapt it to the entire protein. We provide biochemical characterization and a high‐resolution X‐ray structure for one variant and compare it to our design model. The successful extension of this robust TIM‐barrel scaffold opens opportunities to diversify it towards more pocket like arrangements and as such can be considered a building block for future design of binding or catalytic sites.     

Rational design of TNFα binding proteins based on the de novo designed protein DS119

De novo protein design offers templates for engineering tailor‐made protein functions and orthogonal protein interaction networks for synthetic biology research. Various computational methods have been developed to introduce functional sites in known protein structures. De novo designed protein scaffolds provide further opportunities for functional protein design. Here we demonstrate the rational design of novel tumor necrosis factor alpha (TNFα) binding proteins using a home‐made grafting program AutoMatch. We grafted three key residues from a virus 2L protein to a de novo designed small protein, DS119, with consideration of backbone flexibility. The designed proteins bind to TNFα with micromolar affinities. We further optimized the interface residues with RosettaDesign and significantly improved the binding capacity of one protein Tbab1‐4. These designed proteins inhibit the activity of TNFα in cellular luciferase assays. Our work illustrates the potential application of the de novo designed protein DS119 in protein engineering, biomedical research, and protein sequence‐structure‐function studies.     

De novo backbone scaffolds for protein design

In recent years, there have been significant advances in the field of computational protein design including the successful computational design of enzymes based on backbone scaffolds from experimentally solved structures. It is likely that large‐scale sampling of protein backbone conformations will become necessary as further progress is made on more complicated systems. Removing the constraint of having to use scaffolds based on known protein backbones is a potential method of solving the problem. With this application in mind, we describe a method to systematically construct a large number of de novo backbone structures from idealized topological forms in a top–down hierarchical approach. The structural properties of these novel backbone scaffolds were analyzed and compared with a set of high‐resolution experimental structures from the protein data bank (PDB). It was found that the Ramachandran plot distribution and relative γ‐ and β‐turn frequencies were similar to those found in the PDB. The de novo scaffolds were sequence designed with RosettaDesign, and the energy distributions and amino acid compositions were comparable with the results for redesigned experimentally solved backbones. Proteins 2010. © 2009 Wiley‐Liss, Inc.     

The advent of de novo proteins for cancer immunotherapy

Engineered proteins are revolutionizing immunotherapy, but advances are still needed to harness their full potential. Traditional protein engineering methods use naturally existing proteins as a starting point, and therefore, are intrinsically limited to small alterations of a protein's natural structure and function. Conversely, computational de novo protein design is free of such limitation, and can produce a virtually infinite number of novel protein sequences, folds, and functions. Recently, we used de novo protein engineering to create Neoleukin-2/15 (Neo-2/15), a protein mimetic of the function of both interleukin-2 (IL-2) and interleukin-15 (IL-15). To our knowledge, Neo-2/15 is the first de novo protein with immunotherapeutic activity, and in murine cancer models, it has demonstrated enhanced therapeutic potency and reduced toxicity compared to IL-2. De novo protein design is already showcasing its tremendous potential for driving the next wave of protein-based therapeutics that are explicitly engineered to treat disease.     

Hotspot-centric de novo design of protein binders

Protein-protein interactions play critical roles in biology, and computational design of interactions could be useful in a range of applications. We describe in detail a general approach to de novo design of protein interactions based on computed, energetically optimized interaction hotspots, which was recently used to produce high-affinity binders of influenza hemagglutinin. We present several alternative approaches to identify and build the key hotspot interactions within both core secondary structural elements and variable loop regions and evaluate the method's performance in natural-interface recapitulation. We show that the method generates binding surfaces that are more conformationally restricted than previous design methods, reducing opportunities for off-target interactions.     

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

The aim of de novo protein design is to find the amino acid sequences that will fold into a desired 3-dimensional structure with improvements in specific properties, such as binding affinity, agonist or antagonist behavior, or stability, relative to the native sequence. Protein design lies at the center of current advances drug design and discovery. Not only does protein design provide predictions for potentially useful drug targets, but it also enhances our understanding of the protein folding process and protein-protein interactions. Experimental methods such as directed evolution have shown success in protein design. However, such methods are restricted by the limited sequence space that can be searched tractably. In contrast, computational design strategies allow for the screening of a much larger set of sequences covering a wide variety of properties and functionality. We have developed a range of computational de novo protein design methods capable of tackling several important areas of protein design. These include the design of monomeric proteins for increased stability and complexes for increased binding affinity.To disseminate these methods for broader use we present Protein WISDOM (http://www.proteinwisdom.org), a tool that provides automated methods for a variety of protein design problems. Structural templates are submitted to initialize the design process. The first stage of design is an optimization sequence selection stage that aims at improving stability through minimization of potential energy in the sequence space. Selected sequences are then run through a fold specificity stage and a binding affinity stage. A rank-ordered list of the sequences for each step of the process, along with relevant designed structures, provides the user with a comprehensive quantitative assessment of the design. Here we provide the details of each design method, as well as several notable experimental successes attained through the use of the methods.     

Principles and Methods in Computational Membrane Protein Design

After decades of progress in computational protein design, the design of proteins folding and functioning in lipid membranes appears today as the next frontier. Some notable successes in the de novo design of simplified model membrane protein systems have helped articulate fundamental principles of protein folding, architecture and interaction in the hydrophobic lipid environment. These principles are reviewed here, together with the computational methods and approaches that were used to identify them. We provide an overview of the methodological innovations in the generation of new protein structures and functions and in the development of membrane-specific energy functions. We highlight the opportunities offered by new machine learning approaches applied to protein design, and by new experimental characterization techniques applied to membrane proteins. Although membrane protein design is in its infancy, it appears more reachable than previously thought.     

De novo reconstruction of DNA origami structures through atomistic molecular dynamics simulation

The DNA origami method has brought nanometer-precision fabrication to molecular biology labs, offering myriads of potential applications in the fields of synthetic biology, medicine, molecular computation, etc. Advancing the method further requires controlling self-assembly down to the atomic scale. Here we demonstrate a computational method that allows the equilibrium structure of a large, complex DNA origami object to be determined to atomic resolution. Through direct comparison with the results of cryo-electron microscopy, we demonstrate de novo reconstruction of a 4.7 megadalton pointer structure by means of fully atomistic molecular dynamics simulations. Furthermore, we show that elastic network-guided simulations performed without solvent can yield similar accuracy at a fraction of the computational cost, making this method an attractive approach for prototyping and validation of self-assembled DNA nanostructures.     

Design principles of protein switches

Protein switches perform essential roles in many biological processes and are exciting targets for de novo protein design, which aims to produce proteins of arbitrary shape and functionality. However, the biophysical requirements for switch function — multiple conformational states, fine-tuned energetics, and stimuli-responsiveness — pose a formidable challenge for design by computation (or intuition). A variety of methods have been developed toward tackling this challenge, usually taking inspiration from the wealth of sequence and structural information available for naturally occurring protein switches. More recently, modular switches have been designed computationally, and new methods have emerged for sampling unexplored structure space, providing promising new avenues toward the generation of purpose-built switches and de novo signaling systems for cellular engineering.     

Deep learning approaches for de novo drug design: An overview

De novo drug design is the process of generating novel lead compounds with desirable pharmacological and physiochemical properties. The application of deep learning (DL) in de novo drug design has become a hot topic, and many DL-based approaches have been developed for molecular generation tasks. Generally, these approaches were developed as per four frameworks: recurrent neural networks; encoder-decoder; reinforcement learning; and generative adversarial networks. In this review, we first introduced the molecular representation and assessment metrics used in DL-based de novo drug design. Then, we summarized the features of each architecture. Finally, the potential challenges and future directions of DL-based molecular generation were prospected.     

Chance Favors the Prepared Mind - From Serendipity to Rational Drug Design

Abstract

Accidental discoveries always played an important role in science, especially in the search for new drugs. Several examples of serendipitous findings, leading to therapeutically useful drugs, are presented and discussed. Captopril, an antihypertensive Angiotensin-converting enzyme inhibitor, was the first drug that could be derived from a structural model of a protein. Dorzolamide, a Carboanhydrase inhibitor for the treatment of glaucoma, and the HIV protease inhibitors Saquinavir, Indinavir, Ritonavir, and Nelfinavir are further examples of therapeutically used drugs from structure-based design. More enzyme inhibitors, e.g. the anti-influenza drugs Zanamivir and GS 4104, are in clinical development. In the absence of a protein 3D structure, the 3D structures of certain ligands may be used for rational design. This approach is exemplified by the design of specifically acting integrin receptor antagonists. In the last years, combinatorial and computational approaches became important methods for rational drug design. SAR by NMR searches for low-affinity ligands that bind to proximal subsites of an enzyme; linkage with an appropriate tether produces nanomolar inhibitors. The de novo design program LUDI and the docking program FlexX are tools for the computer-aided design of protein ligands. Work is in progress to combine such approaches to strategies for combinatorial drug design.

Dans les champs de l'obsérvation le hasard ne favorise que les ésprits préparés. Louis Pasteur (1822–1895)     

Integrating structure-based approaches in generative molecular design

Generative molecular design for drug discovery and development has seen a recent resurgence promising to improve the efficiency of the design-make-test-analyse cycle; by computationally exploring much larger chemical spaces than traditional virtual screening techniques. However, most generative models thus far have only utilized small-molecule information to train and condition de novo molecule generators. Here, we instead focus on recent approaches that incorporate protein structure into de novo molecule optimization in an attempt to maximize the predicted on-target binding affinity of generated molecules. We summarize these structure integration principles into either distribution learning or goal-directed optimization and for each case whether the approach is protein structure-explicit or implicit with respect to the generative model. We discuss recent approaches in the context of this categorization and provide our perspective on the future direction of the field.     

The Stability Landscape of de novo TIM Barrels Explored by a Modular Design Approach

The ability to design stable proteins with custom-made functions is a major goal in biochemistry with practical relevance for our environment and society. Understanding and manipulating protein stability provide crucial information on the molecular determinants that modulate structure and stability, and expand the applications of de novo proteins. Since the (β/⍺)₈-barrel or TIM-barrel fold is one of the most common functional scaffolds, in this work we designed a collection of stable de novo TIM barrels (DeNovoTIMs), using a computational fixed-backbone and modular approach based on improved hydrophobic packing of sTIM11, the first validated de novo TIM barrel, and subjected them to a thorough folding analysis. DeNovoTIMs navigate a region of the stability landscape previously uncharted by natural TIM barrels, with variations spanning 60 degrees in melting temperature and 22 kcal per mol in conformational stability throughout the designs. Significant non-additive or epistatic effects were observed when stabilizing mutations from different regions of the barrel were combined. The molecular basis of epistasis in DeNovoTIMs appears to be related to the extension of the hydrophobic cores. This study is an important step towards the fine-tuned modulation of protein stability by design.     

Shotgun Protein Sequencing with Meta-contig Assembly

Full-length de novo sequencing from tandem mass (MS/MS) spectra of unknown proteins such as antibodies or proteins from organisms with unsequenced genomes remains a challenging open problem. Conventional algorithms designed to individually sequence each MS/MS spectrum are limited by incomplete peptide fragmentation or low signal to noise ratios and tend to result in short de novo sequences at low sequencing accuracy. Our shotgun protein sequencing (SPS) approach was developed to ameliorate these limitations by first finding groups of unidentified spectra from the same peptides (contigs) and then deriving a consensus de novo sequence for each assembled set of spectra (contig sequences). But whereas SPS enables much more accurate reconstruction of de novo sequences longer than can be recovered from individual MS/MS spectra, it still requires error-tolerant matching to homologous proteins to group smaller contig sequences into full-length protein sequences, thus limiting its effectiveness on sequences from poorly annotated proteins. Using low and high resolution CID and high resolution HCD MS/MS spectra, we address this limitation with a Meta-SPS algorithm designed to overlap and further assemble SPS contigs into Meta-SPS de novo contig sequences extending as long as 100 amino acids at over 97% accuracy without requiring any knowledge of homologous protein sequences. We demonstrate Meta-SPS using distinct MS/MS data sets obtained with separate enzymatic digestions and discuss how the remaining de novo sequencing limitations relate to MS/MS acquisition settings.Database search tools, such as Sequest (3), Mascot (4), and InsPecT (5), are the most frequently used methods for reliable protein identification in tandem mass (MS/MS) spectrometry based proteomics. These operate by separately matching each MS/MS spectrum to peptide sequences from reference protein databases where all proteins of interest are presumably contained. But this assumption often does not hold true as many important proteins, such as monoclonal antibodies, are not contained in any database because mechanisms of antibody variation (including genetic recombination and somatic hyper-mutation (6)) constantly create new proteins with novel unique sequences. These mechanisms of variation are the foundation of adaptive immune systems and have enabled highly successful antibody-based therapeutic strategies (7, 8). Nevertheless, such variation also means that antibody MS/MS spectra are typically impossible to identify via standard database search techniques whenever the corresponding sequences are not known in advance. An inherent drawback of database search strategies is that they are only as good as the database(s) being searched and incomplete databases often result in proteins being misidentified or left unidentified (9).Despite the importance of novel protein identification, few high-throughput methods have been developed for de novo sequencing of unknown proteins. Low-throughput Edman degradation is a well-known de novo sequencing approach that can accurately call amino acid sequences in N/C-terminal regions of unknown proteins but has drawbacks that make it unsuitable for sequencing proteins longer than 50 amino acids or proteins with post-translational modifications (10, 11). Many have recognized the potential of tandem mass spectrometry for protein sequencing. For example, in 1987 Johnson and Biemann (12) manually sequenced a complete protein from rabbit bone marrow. Meanwhile, automated de novo sequencing methods that rely on interpretations of individual MS/MS spectra are limited in that they typically cannot reconstruct long (8+ AA) sequences without mis-predicting 1 in 5 AA on average for low accuracy collision-induced dissociation (CID) spectra (13, 14). Recent advances in de novo peptide sequencing have improved sequencing accuracy to over 95% for high resolution higher energy collisional dissociation (HCD)¹ spectra (15), but at limited sequence coverage (Chi H et al. report only 55% sequence coverage of peptides identified by database search). In fact, all current per-spectrum de novo sequencing strategies face a significant tradeoff between sequencing accuracy and coverage as spectra exhibiting complete peptide fragmentation rarely cover entire target proteins, yet are required to accurately reconstruct full-length peptide sequences. An alternative approach to separately sequencing individual spectra is to simultaneously interpret multiple MS/MS spectra from overlapping peptides. This Shotgun Protein Sequencing (SPS) paradigm differs from traditional algorithms by deriving consensus sequences from contigs - sets of multiple MS/MS spectra from distinct peptides with overlapping sequences (1, 16). Because SPS aggregates multiple spectra from overlapping peptides, protein sequences extending beyond the length of enzymatically digested peptides can be extracted from spectra with incomplete peptide fragmentation. Furthermore, SPS has been found to generate sequences that frequently cover 90–95+% of the target protein sequence(s) whereas mis-predicting only 1 out of every 20 amino acids on high resolution MS/MS spectra (2). But a remaining limitation of SPS is that it still generates fragmented sequences that do not singularly cover large regions of the target protein sequences, much less complete proteins: SPS sequences have an average length of 10–15 amino acids (depending on input data) and the longest recovered SPS de novo sequence is less than 45 amino acids long (1).The considerable limitations of de novo sequencing strategies have typically been addressed by attempting to circumvent them using error-tolerant matching to known protein sequences. One such strategy (17) is to generate short de novo sequence tags and then match them exactly to protein databases without requiring matching the N/C-term flanking masses (to allow for unexpected polymorphisms or post-translational modifications). Short sequence tags are usually derived from parts of the spectrum with high signal-to-noise ratios and typically have higher sequencing accuracy than full-length de novo sequences (18). This approach was later extended in MS-Shotgun (19) and continues to be a popular technique for speeding up database search tools (5, 20–22). Homology matching of full length de novo sequences was first explored in CIDentify (23) and later in MS-BLAST (24) by searching de novo sequences using FASTA and WU-BLAST2 (respectively) to find homologous matches to sequences of related proteins; FASTS (25) also approached the problem using a modified version of FASTA. However, common de novo sequencing errors tend to produce sequences that are heavily penalized in pure sequence homology searches. For example, missing peaks in MS/MS spectra may easily cause GA subsequences to be reconstructed as Q or AG (same-mass sequences), thus making subsequent BLAST searches unlikely to succeed. This issue was partially considered in CIDentify and more thoroughly addressed in SPIDER (26) by explicitly modeling de novo sequencing errors together with BLOSUM scores in MS/MS-based sequence homology searches. In addition, OpenSea (27) further explored database matching of de novo sequences for analysis of unexpected post-translational modifications (PTMs). Finally, Shen et al. (28) used short unique de novo sequence tags, called UStags, to discover protein-localized PTMs.Recent approaches to homology matching of de novo sequences have built on genome assembly and sequencing techniques to achieve database-assisted full-length sequencing of unknown proteins. Comparative Shotgun Protein Sequencing (cSPS) complemented SPS assembly techniques with usage of error tolerant matching of de novo sequences to find overlapping SPS de novo sequences that are then further assembled into full-length protein sequences (2). cSPS was designed to support the sequencing of highly divergent proteins that have regions close enough in homology to transfer matches from a reference. cSPS was shown to enable de novo sequencing of monoclonal antibodies at 95+% sequencing accuracy, while simultaneously tolerating and identifying unexpected PTMs (29). In difference from cSPS, Champs (30) de novo sequences individual spectra to obtain putative peptide sequences, which are then mapped to homologous proteins to correct sequencing errors and reconstruct protein sequences with 100% accuracy and 99% coverage. However, Champs is designed to only map peptides that differ from the reference sequence by one or two amino acids and does not handle PTMs. As such, its sequencing accuracy is not directly comparable to that of cSPS as Champs was not designed to sequence highly divergent proteins (such as monoclonal antibodies) with multiple PTMs, insertions, deletions, and/or recombinations. GenoMS (31) extended the approaches in cSPS/Champs by explicitly modeling protein splice variants as paths in splice graphs where nodes represent translated exon regions (32). MS/MS spectra are first searched for exact sequence matches against all possible protein isoforms. The remaining unidentified MS/MS spectra are then aligned to the matched peptides and de novo sequenced to extend the matched sequences into novel regions. Reported sequences are 97–99% accurate and cover 96–99% of target proteins depending on sequence similarity between the novel and reference sequences (31). However, GenoMS de novo sequences are usually extended less than 3 amino acids beyond matched peptides because sequencing accuracy degrades as sequences are extended, thus preventing the consistent extension of long (10+ AA) sequences. Altogether, the use of homology matching approaches for full-length de novo protein sequencing continues to be limited by 1) requiring the previous knowledge of closely related protein sequences and 2) the inherent difficulties in statistically significant homology-tolerant matching of error-prone short de novo sequences.The Meta-SPS approach proposed here seeks to de novo sequence complete proteins, or long protein regions, without any use of a database. Meta-SPS builds upon SPS by treating SPS de novo sequences (contig sequences) as input spectra and further assembling them into longer de novo sequences (meta-contig sequences). We show that Meta-SPS extends de novo sequences to lengths over 100 AA while boosting sequencing accuracy to only 1 mistake per 40 amino acid predictions, thus enabling database-free de novo sequencing of completely novel proteins while also allowing error-tolerant matching approaches to support higher-divergence homologies (by searching longer, more accurate de novo sequences). Meta-SPS algorithms are demonstrated on CID and HCD MS/MS spectra and its limitations are discussed in relation to the underlying limitations of bottom-up tandem mass spectrometry.     

Design and structure of two new protein cages illustrate successes and ongoing challenges in protein engineering

In recent years, new protein engineering methods have produced more than a dozen symmetric, self‐assembling protein cages whose structures have been validated to match their design models with near‐atomic accuracy. However, many protein cage designs that are tested in the lab do not form the desired assembly, and improving the success rate of design has been a point of recent emphasis. Here we present two protein structures solved by X‐ray crystallography of designed protein oligomers that form two‐component cages with tetrahedral symmetry. To improve on the past tendency toward poorly soluble protein, we used a computational protocol that favors the formation of hydrogen‐bonding networks over exclusively hydrophobic interactions to stabilize the designed protein–protein interfaces. Preliminary characterization showed highly soluble expression, and solution studies indicated successful cage formation by both designed proteins. For one of the designs, a crystal structure confirmed at high resolution that the intended tetrahedral cage was formed, though several flipped amino acid side chain rotamers resulted in an interface that deviates from the precise hydrogen‐bonding pattern that was intended. A structure of the other designed cage showed that, under the conditions where crystals were obtained, a noncage structure was formed wherein a porous 3D protein network in space group I2₁3 is generated by an off‐target twofold homomeric interface. These results illustrate some of the ongoing challenges of developing computational methods for polar interface design, and add two potentially valuable new entries to the growing list of engineered protein materials for downstream applications.     

Sequencing enabling design and learning in synthetic biology

The ability to read and quantify nucleic acids such as DNA and RNA using sequencing technologies has revolutionized our understanding of life. With the emergence of synthetic biology, these tools are now being put to work in new ways — enabling de novo biological design. Here, we show how sequencing is supporting the creation of a new wave of biological parts and systems, as well as providing the vast data sets needed for the machine learning of design rules for predictive bioengineering. However, we believe this is only the tip of the iceberg and end by providing an outlook on recent advances that will likely broaden the role of sequencing in synthetic biology and its deployment in real-world environments.     

A newly introduced salt bridge cluster improves structural and biophysical properties of de novo TIM barrels

Protein stability can be fine‐tuned by modifying different structural features such as hydrogen‐bond networks, salt bridges, hydrophobic cores, or disulfide bridges. Among these, stabilization by salt bridges is a major challenge in protein design and engineering since their stabilizing effects show a high dependence on the structural environment in the protein, and therefore are difficult to predict and model. In this work, we explore the effects on structure and stability of an introduced salt bridge cluster in the context of three different de novo TIM barrels. The salt bridge variants exhibit similar thermostability in comparison with their parental designs but important differences in the conformational stability at 25°C can be observed such as a highly stabilizing effect for two of the proteins but a destabilizing effect to the third. Analysis of the formed geometries of the salt bridge cluster in the crystal structures show either highly ordered salt bridge clusters or only single salt bridges. Rosetta modeling of the salt bridge clusters results in a good prediction of the tendency on stability changes but not the geometries observed in the three‐dimensional structures. The results show that despite the similarities in protein fold, the salt bridge clusters differently influence the structural and stability properties of the de novo TIM barrel variants depending on the structural background where they are introduced.